News Releases
Pediatric Ear Rx Gets FDA Nod
SAN DIEGO, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that the U.S. Food and Drug Administration (FDA) has approved OTIPRIO (ciprofloxacin otic suspension) for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement.
A Plan to Help the Pre-existing Condition Crowd
The U.S. Department of Health and Human Services (HHS) is increasing awareness about a health plan for uninsured Americans with pre-existing conditions created by the Affordable Care Act.